Reply
- PMID: 36402373
- DOI: 10.1016/j.cgh.2022.11.006
Reply
Comment on
-
Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?Clin Gastroenterol Hepatol. 2023 Aug;21(9):2430-2431. doi: 10.1016/j.cgh.2022.09.015. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36155249 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources